Prexa Pharmaceuticals Secures $7,000,000 Series B Funding

  • Feed Type
  • Date
    5/11/2011
  • Company Name
    Prexa Pharmaceuticals
  • Mailing Address
    184 High St. Boston, MA 02110
  • Company Description
    Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease.
  • Website
    http://www.prexainc.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $7,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will allow thecompany to complete IND-enabling studies through Phase 1b clinical studies for its lead productcandidate PRX-12251.
  • M&A Terms
  • Venture Investor
    Advent Healthcare Ventures
  • Venture Investor
    Shire Pharmaceuticals
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.